# Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) is the first and only subcutaneously administered therapy for epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) Compared to

*biotech · news · 2025-12-18 · Benzinga*

## Key points

- FDA approved Rybrevant Faspro as the first subcutaneous therapy for EGFR-mutated NSCLC.
- Rybrevant Faspro reduces administration time to five minutes and lowers adverse reactions versus IV.
- SC Rybrevant showed longer duration of response, progression-free survival, and overall survival than IV.
- FDA expanded TRUFILL n-BCA approval for embolization of the MMA to treat subdural hematoma.

**Companies:** Johnson & Johnson
**Countries:** United States

[Read the full story on Benzinga](https://www.benzinga.com/news/fda/25/12/49490895/fda-approves-jjs-new-5-minute-injection-for-lung-cancer)

---

Canonical: https://newsio.io/n/d904eaed-8ff3-4df3-852f-e448ae3e7e5e/rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-is-the-first-and-only-subcut
Summarized by Newsio from Benzinga. https://newsio.io/how-it-works